Please find enclosed herewith the Annual Secretarial Compliance Report for the year ended March 31, 2026.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bliss GVS Pharma Ltd has filed its Annual Secretarial Compliance Report for FY ended March 31, 2026, as required under SEBI Listing Regulations. The report by AVS & Associates shows the company largely complied with SEBI regulations including LODR, ICDR, SAST, PIT, and Depositories regulations. However, one insider trading contravention was identified - a Designated Person executed a contra trade, triggering Regulation 9 of SEBI (PIT) Regulations, and the company is taking corrective action. Additionally, two past compliance delays from FY 2024-25 were noted: delayed FDA license suspension disclosure (1 day) and delayed senior management cessation disclosure (15 days). The company had also paid fines of Rs 66,000 each to BSE and NSE for appointing a director aged over 75 without prior shareholder approval. The secretarial auditor confirmed all 13 compliance checkpoints were met.
No material compliance breach is indicated. The insider trading contravention is being addressed internally, suggesting proactive governance. The resolution of past delays and fine payments demonstrates compliance intent, which is marginally positive for investors.